In Enterobacter cloacae and Serratia marcescens, AmpC β-lactamases can confer resistance to the third-generation cephalosporins and oxacephems, but not to the fourth-generation cephalosporins. Extended-spectrum β-lactamases (ESBL) may confer resistance to all extended-spectrum cephalosporins but not flomoxef. As difficult to detect, the ESBL phenotype of the intrinsically AmpCproducing E. cloacae and S. marcescens is not routinely screened in the clinical microbiology laboratories. The distinct antibiotic resistance phenotype between ESBL-and AmpC-producers may assist to differentiate the type of secreted β-lactamases. Therefore, we attested the validity of an antibiogram-based method to predict the presence of ESBLs in both species. METHODS: Polymerase chain reaction-based methods and antibiogram-based methods were compared for their detection of ESBL in 74 E. cloacae and 69 S. marcescens isolates recovered from patients hospitalized at two medical centers in Taiwan. Three major types of antibiogram were defined: type I (3s4s), susceptible to cefotaxime, ceftazidime, and cefepime; type II (3r4s), resistant to cefotaxime or ceftazidime, but susceptible to cefepime; and type III (3r4r), resistant to cefepime plus cefotaxime and/or ceftazidime. Furthermore, subtype-a and subtype-b were defined as being resistant and susceptible to flomoxef, respectively. RESULTS: Overall, ESBL producers were identified in 20 (27.0%) of Enterobacter and 11 (15.9%) of Serratia isolates by polymerase chain reaction-based methods. All type I isolates of both species (n = 49) were non-ESBL
Introduction
Plasmid-mediated extended-spectrum β-lactamases (ESBL), derived mainly from Temoniera (TEM)-type and sulfhydryl variable (SHV)-type β-lactamases, are able to confer resistance to all extended-spectrum oxyiminocephalosporins (e.g. cefotaxime, ceftazidime, and cefepime), and monobactams (e.g. aztreonam). 1 ESBLs do not hydrolyze 7-α-methoxy β-lactams, including cephamycins (e.g. cefoxitin and cefotetan) or oxacephems (e.g. moxalactam and flomoxef). 2 Since the first report of Klebsiella pneumoniae expressing an ESBL was published in 1983, 3 the frequency of ESBL-producing Enterobacteriaceae has increased, and encompasses Escherichia coli and other organisms with chromosomal Bush group 1 (AmpC) β-lactamase, such as Enterobacter spp., Citrobacter spp., and Serratia spp. [4] [5] [6] [7] [8] [9] Production of small amounts of inducible AmpC β-lactamases causes intrinsic resistance of the AmpC producers to ampicillin and first-generation cephalosporins. Antibiotic induction of high AmpC β-lactamase leads to expression or selection of derepressed mutants, which produce high levels of the AmpC β-lactamase, [10] [11] [12] has conferred resistance to 7-α-methoxy β-lactams and to all cephalosporins except the fourth-generation agents (e.g. cefepime and cefpirome). 2 The distinct antibiotic resistance phenotypes (antibiogram) between ESBL-and AmpC-producers may assist to differentiate the type of secreted β-lactamase. Gene or protein sequencing is used for accurate identification of the Enterobacteriaceae β-lactamases. ESBL production can be screened by both cefotaxime and ceftazidime, alone and in combination with clavulanate using phenotypic disks. [13] [14] [15] The Clinical and Laboratory Standards Institute has issued recommendations for ESBL screening and confirmation for isolates of E. coli, K. pneumoniae, K. oxytoca, and Proteus mirabilis, but not for AmpC-producing organisms. 16, 17 Although phenotypic disk methods can be applied to AmpC producers, the major concern is that high-level expression of AmpC may prevent recognition of an ESBL in an AmpC-inducible species.
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ESBL-producing isolates of Enterobacter cloacae and Serratia marcescens have been identified in several hospitals in Taiwan. 18-25 However, most clinical microbiology laboratories do not currently screen for ESBL in E. cloacae and S. marcescens on a routine basis. Therefore, clinical physicians need alternative ways to recognize these ESBLproducing bacteria, such as an antibiogram-based method. Accordingly, the present study assesses the reliability of the antibiogram-based method using a panel containing cefotaxime, ceftazidime, cefepime, and flomoxef to predict the presence or absence of ESBLs in a consecutive collection of clinical isolates of E. cloacae and S. marcescens. We initially hypothesized that ESBLs occurred in isolates with an antibiogram of resistance to ceftazidime, cefotaxime, and/or cefepime but susceptibility to flomoxef; whereas isolates with resistance to ceftazidime, cefotaxime and flomoxef, but susceptibility to cefepime, implied a predominant expression of AmpC β-lactamase.
Methods

Bacterial strains
Non-repetitive E. cloacae clinical isolates (n = 74) were obtained from patients hospitalized at a university affiliated medical center in Central Taiwan from January 1 to June 30, 
Confirmation test of ESBL phenotype
The combination-disk synergistic test (CDST) using cefotaxime, ceftazidime, and cefepime plus clavulanate (10 μg) was performed to detect ESBL production for all isolates. 
Statistical analysis
The PCR-based method was used as the standard detection method with the accuracy of ESBL detection results by other methods evaluated by sensitivity, specificity, positive predictive value, and negative predictive value. 
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Results
Bacterial strains, sources, and ESBL survey
Among the 74 non-repetitive E. cloacae isolates, 32 (43.2%) recovered from wound pus, 21 (28.4%) from urine, six (8.1%) from blood, six (8.1%) from central venous catheter tip, three (4.1%) from ascites, two (2.7%) from sputum, and four (5.4%) from other sources ( Table 2 ). The CDST or the MIC-based methods were able to detect 16 ESBL producers ( Table 3 ). The 74 isolates were surveyed for ESBL genes using PCR, which detected 4 additional ESBL producers (strains E11, E24, E34, and E35). Therefore, the sensitivity, specificity, positive predictive value, and negative predictive value of the CDST or the MIC-based method for ESBL detection in E. cloacae was 80.0%, 100%, 100%, and 93.1%, respectively. Twenty (27.0%) isolates carried alleles for the bla SHV-12 gene (Table 4) . Subsequent DNA sequencing of all PCR products confirmed 100% homology to the bla SHV-12 gene. The E95 and E96 isolates also contained bla CTX-M- 14 and bla CTX-M-3 , respectively. TEM-1 β-lactamase was confirmed in 10 non-ESBL isolates. The ESBL producers were most commonly isolated from central venous catheter-tip, urine, ascites, and pus specimens ( Table 2) .
From 69 bacteremic isolates of S. marcescens, the CDST or MIC-based methods were able to detect nine ESBL producers (Table 5 ) while a total of 11 ESBL producers were identified by PCR, including 10 isolates producing CTX-M-3 and one producing SHV-12 ( Table 6 ). The sensitivity, false negative result when phenotypic disk and MIC-based extended-spectrum β-lactamases detection methods were employed (see Table 5 ). ESBL = extended-spectrum β-lactamases; CAZ = ceftazidime; CTX = cefotaxime; FEP = cefepime; FLO = flomoxef; CDST = combination-disk synergistic test; MIC = minimum inhibitory concentration; PCR = polymerase chain reaction ; PPV = positive predictive value; NPV = negative predictive value; S = susceptible; R = resistant. (Table 5) .
Antibiogram
Antibiograms of the 74 E. cloacae isolates revealed susceptibility profiles to cefotaxime, ceftazidime, and cefepime, and were classified into three major types (Types I-III). Each type could be further classified into subtype-a (resistant to flomoxef) or subtype-b (susceptible to flomoxef) ( Table 3) . Type I (3s4s) isolates (n = 45) were susceptible to cefotaxime, ceftazidime, and cefepime, and were all non-ESBL producers. All ESBL producers were distributed among the type II (3r4s) and III (3r4r) E. cloacae isolates. 
Survey for chromosomal AmpC gene
The alleles of AmpC gene in the 29 E. cloacae isolates with antibiogram types II and III were characterized by PCR. Each isolate produced a 1,165-bp PCR fragment containing the AmpC gene. Subsequent DNA sequencing of the PCR products from strains E71 and E11 revealed 99% and 97% identity to bla(EcloK995120.1) and bla (EcloK9973), respectively, which were the chromosomal AmpC gene of E. cloacae found in Korea. 27 Furthermore, false negative results by phenotypic disk and MIC-based extended-spectrum β-lactamases detection methods (see Table 6 ). ESBL = extendedspectrum β-lactamases; CAZ = ceftazidime; CTX = cefotaxime; FEP = cefepime; FLO = flomoxef; CDST = combination-disk synergistic test; MIC = minimum inhibitory concentration; PCR = polymerase chain reaction; PPC = positive predictive value; NPV = negative predictive value; S = susceptible; R = resistant. 
MIC determination
Detailed MIC values and ESBL genotypes of the ESBLproducing E. cloacae isolates (n = 20) and S. marcescens isolates (n = 11) can be found in Tables 4 and 6 , respectively. The MICs of cefotaxime, ceftazidime, and cefepime for the 20 Enterobacter ESBL producers ranged from 8 to 512 μg/ mL, 8 to > 512 μg/mL, and 0.5 to 32 μg/mL, respectively. Of the 20 Enterobacter ESBL producers, 70.0% (14/20) were susceptible to cefepime (MIC < 8 μg/mL). A significant reduction of MICs for cefotaxime, ceftazidime, and cefepime in the presence of clavulanate was not achieved for four Enterobacter ESBL producers (strains E11, E24, E34, and E35) and two Serratia ESBL producers (strains no. 109 and 122).
Discussion
This analysis determined that the antibiogram-based method might be used as an initial screening method for ESBL detection in E. cloacae and S. marcescens. The antibiograms of subtype IIb and type III are highly predictive of ESBL detection in E. cloacae, whilst the antibiogram of type III is highly predictive of ESBL detection in S. marcescens. The type I antibiogram is highly predictive of non-ESBL producers for both species.
Many studies have reported a diverse prevalence of resistant strains of Enterobacter spp. and S. marcescens that produce plasmid-mediated ESBLs. 4, 5, [7] [8] [9] [18] [19] [20] [21] [22] [23] [24] [25] 29, 30 The increasing reports of ESBL-producing Enterobacter and Serratia isolates in Taiwan emphasizes the need for a better understanding of ESBL production in clinical isolates. However, ESBL detection can be challenging, because the inhibitor-based method can be confounded by the high level production of AmpC enzymes which are resistant to clavulanate. Some investigators suggested that an elevated MIC of cefepime > 0.25 μg/mL, 8 or ≥ 1 μg/mL, 9 has the highest sensitivity (100% and 95.3%, respectively) and specificity (74% and 82.7%, respectively) for the presence of an ESBL. Similarly, no non-ESBL producing E. cloacae strains had MICs of cefepime ≥ 2 μg/mL. 31 However, most clinical microbiology laboratories perform the disk diffusion method to measure antibiotic susceptibility on a routine basis and do not use MIC-based techniques in Taiwan.
Thus the disk antibiogram-based method may be an acceptable strategy for ESBL screening.
Isolates of Enterobacter and Serratia with concurrent susceptibilities to cefotaxime, ceftazidime, and cefepime (type I antibiogram), implying minimal or no induction of the chromosomal AmpC enzymes, have a low likelihood of ESBL production. Similar to our results, were those from a report in Korea stating the susceptibility of the ESBL producers E. cloacae, C. freundii, and S. marcescens to ceftazidime, cefotaxime, and aztreonam (MICs < 8 μg/ mL each) was very low (0.04-0.27%). 9 These facts suggest that these ESBL-producing organisms rarely maintain simultaneous susceptibility to all extended-spectrum cephalosporins. Thus it seems unnecessary to perform an ESBL test for isolates with a type I antibiogram, because the likelihood of a false negative result that might lead to inadequate treatment is negligible. The mechanisms conferring resistance to the cephalosporins tested in our study are multifactorial. Isolates of subtype Ia with resistance to flomoxef likely exhibited an outer membrane protein defect. 32 The The mortality of patients from E. cloacae bacteremia is significantly higher in ESBL carriers with most harboring SHV-12 when compared with non-ESBL carriers. 19 Additionally, reduced susceptibility to cefepime among ESBL producers in the members of Enterobacteriaceae has become a major reason for potential therapeutic failure. 29, 31, 33 The possibly high rates of susceptibility to cefepime by ESBL producers re-emphasizes the importance for clinical physicians to be able to recognize ESBL production in E. cloacae and S. marcescens. With the aid of the antibiogram-based ESBL screening method described in our study, targeting effective antimicrobials to patients harboring ESBL producers is possible. Since these specimens were isolated only from Taiwan, its applicability to other geographical populations warrants further study. In conclusion, despite that the Clinical and Laboratory Standards Institute methods are not issued for the detection of E. cloacae and S. marcescens EBSL, we suggest a simple and reliable method for physicians to detect ESBL production among these AmpC producers. For S. marcescens, ESBLs commonly occurred in isolates with a type III antibiogram; in E. cloacae, ESBLs frequently occurred in isolates with type III or subtype IIb antibiogram. However, ESBLs also occurred in some of the subtype IIa strains. Therefore, further ESBL testing should be focused on the subtype IIa Enterobacter isolates. Our antibiogram-based method may simplify the screening of potential ESBLproducing populations among AmpC-producing organisms.
